In Brief: Becton Dickinson
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson: Firm's goal of doubling the size of the company within five years will likely include acquisitions aimed at broadening its core businesses, which include injection systems, vascular access devices, flow cytometry technology, infectious disease diagnostics, sample collection and tissue culture products, the company says. Growth also will come through geographic expansion, such as in the Asia-Pacific region ("The Gray Sheet" Aug. 11, I&W-11), and internal product development. Over the next several years BD plans to increase the percentage of revenues it derives from products introduced within the previous three years to 25% from 15%. In addition, the company has set a target of achieving 10% annual revenue growth by the year 2000...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.